All News

Your daily dose of the clinical news you may have missed.

A nephrology expert reviews how workflow constraints and care delivery pressures affect adherence to guideline-recommended responses to elevated urine albumin-to-creatinine ratio.

The AHA and ACC commend the focus on fruits, vegetables, and whole grains but caution against high-fat dairy and protein emphasis.

Your daily dose of the clinical news you may have missed.

New data from the DROP-AD study suggests that dried blood spots could revolutionize screening approaches for clinical trials.

Your daily dose of the clinical news you may have missed.

COVID-19 vaccination before infection significantly reduces hospitalization, critical care admissions, and preterm birth rates in pregnant individuals, study finds.

Your daily dose of the clinical news you may have missed.

FDA prioritizes review of Tzield for young children with stage 2 type 1 diabetes, potentially delaying disease onset and improving patient outcomes.

The FDA has accepted a supplemental NDA for AXS-05 for agitation associated with Alzheimer disease and granted Priority Review, with a PDUFA action date of April 30, 2026.

Take a quick look back at developments this year with our higlights of acceleration of DMTs, particularly focusing on anti-amyloid antibodies and novel oral agents.

Clevenger explains how better recognition of agitation in Alzheimer disease, and stronger caregiver–clinician communication, can meaningfully improve outcomes.

A multidisciplinary panel of neurologists, geriatricians, and researchers examined how early identification, equitable access, and value-based models could reshape Alzheimer disease care.

Stay informed with the latest critical updates, including new guidelines, vaccine insights, and groundbreaking research findings from 2025.

The FDA approved once-daily oral semaglutide 25 mg for chronic weight management and long-term weight maintenance in adults with obesity or overweight, based on data from the OASIS clinical trial program.

Abbott's Volt PFA System gains FDA approval, offering a new minimally invasive treatment for atrial fibrillation, enhancing patient care options.

Topline Phase 3 ATTAIN-MAINTAIN data show oral orforglipron met primary and key secondary endpoints for weight maintenance after prior GLP-1–based injectable therapy in adults with obesity.

Completion of the screening pathway—not test selection alone—may define quality going forward.